CD30 CAR-T in the Treatment of CD30 Positive Lymphoma
Clinical trial NCT07048353 · NOT_YET_RECRUITING
Trial details
- NCT number
- NCT07048353
- Sponsor
- Shandong Qilu Cell Therapy Engineering Technology Co., Ltd
- Status
- NOT_YET_RECRUITING
- Phase
- Early Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2025-07-28
- Primary completion
- 2029-07-28
- Enrollment
- 15
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.